Uninsured costs range from the mid-hundreds to low thousands per month Tirzepatide GLP-1 & GIP dual receptor agonist : (as semaglutide, plus fat metabolism, insulin sensitivity, and enhanced satiety) SURMOUNT 1 20.9% (72 weeks) SURMOUNT 5 (40 weeks, BMI 40): -20.2% ~2021% average loss 20% loss in ~36% of users 25% in ~25% (up to 40% in SURMOUNT-3) 15mg weekly Nausea (52%) Diarrhea (33%) Vomiting (25%) Constipation (25%) Higher rate of initial GI symptoms vs
In terms of average weight loss seen in large-scale randomised controlled trials, tirzepatide (Mounjaro) has generally outperformed semaglutide (Wegovy)
At baseline, the mean age was 56 years (range 19 to 79), 52% were female, 84% were White, 6% were Asian and 9% were Black or African American
those with low capacity will have Michaelis constants close to clinically relevant concentrations
We might be promoting something that is banned and illegal, and people might think that its ok